Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| So, a pretty exciting year with respect to the number of milestones that are going to be forthcoming and hopefully be able to enhance shareholder value |
| So there's a lot that I think the government is very proud of and Meiji is very proud of |
| Following favorable clinical results from several Kostaive studies, including a 16,000 subject efficacy study performed in Vietnam, as well as a Phase 3 COVID-19 booster trial in Japan, the Japan's Ministry of Health, Labor and Welfare, MHLW, granted approval for Kostaive, a self-amplifying mRNA COVID-19 vaccine for primary vaccination and booster for adults 18 years and older |
| So, they bet on the right horse and I think it's going to be an exciting future |
| And we are increasingly confident about the future applications of our now proven innovative STARR self-amplifying messenger RNA vaccine platform |
| So, we're pretty excited and certainly have the resources to be able to address the CF opportunity and the OTC opportunity and now we're going to be launching two additional vaccines and hopefully, be able to see some progress in that in the next few years |
| The new analysis at six months post vaccination shows that Kostaive induces a broader and more durable immune response compared to Comirnaty for both the original Wuhan strain and the Omicron BA.4/5 variant and an advantage in antibody persistence |
| I am happy to report that everyone was very excited about the approval of Kostaive in Japan and the opportunity to manufacture the world's first self-amplifying mRNA vaccine in Japan under the Meiji-brand |
| And the only thing I would add to that is that Meiji has a strong track record with working with the government to help with these subsidized vaccines in the flu space |
| So that is pretty exciting |
| So these developments, of course, are very good news for us because we're addressing a need of durability for the field, but also that there's elevated support for the elderly and those with underlying medical conditions and healthcare workers in Japan, and that their vaccinations remain free of charge, which of course is going to be helpful to us commercially |
| We continue to make excellent progress, and we are incredibly excited about our first product approval with Kostaive |
| In summary, we believe the company remains in a strong financial position and has the resources to achieve multiple near-term value creating milestones for the vaccine and therapeutic programs |
| Our technologies are ideally suited for these infectious disease vaccine opportunities |
| This demonstrates management's commitment to continually improving shareholder value as we execute our strategic business plan |
| Something that we'd be very encouraged by is to show safety and tolerability of multiple treatments in a spectrum of OTC deficient patients |
| So that's quite substantial, right? And so we're very excited about the opportunity, and it's not trivial |
| Based on the totality of clinical data collected to date, Arcturus anticipates that the advantages of self-amplifying mRNA should provide superior protective efficacy against COVID-19 disease caused by future emergent variants of SARS-CoV-2 |
| We also made significant progress with the BARDA pandemic flu vaccine agreement that led to an increase in revenue of $8.8 million |
| We are very pleased to report that Kostaive remains on track to launch in Japan this year |
| ARCT-810 could reduce the need for ammonia scavengers and ease the rigid dietary protein restrictions that OTC patients face today, thus improving the quality of life for those with this disease |
| So, it will obviously be very significant and meaningful for us, and we're excited about the partnership to be working with all three people in Japan, especially Meiji they're the number one flu vaccine company in Japan and CSL who's number two in the world |
| We're very happy to see that they recommended regular COVID vaccination, especially in the elderly, and the fact that they've recommended two boosters annually |
| And we're pretty excited |
| A significantly stronger and broader immune response is preferred |
| So we have a really strong core of partners to help us fill a void, where until ARCALIS is able to get up to speed |
| And it was very good to hear that the government of Japan is going to be providing these vaccinations to the elderly free of charge |
| So, we're highly excited about that, too |
| And the government -- and we're very fortunate that they gave us this opportunity to compare our vaccine to Pfizer, right? And if we didn't have that opportunity, we would not have this kind of data to share with the world and the fact that they financially supported the factory |
| First, it was encouraging to see the ACIP recommendation on revaccination of the elderly last week |
| Statement |
|---|
| That's going to be about most importance because that's one of the challenges that many other competitors and people that have tried to do lipid nanoparticle mRNA therapeutics for OTC deficiency have failed in the past due to toxicity |
| And what they've shared with us is that, if you do see challenges or problems in toxicology with inhaled therapeutics, it's in the first two administrations |
| The majority of the decrease in FY 2023 revenue was driven by the discontinuation of our collaboration agreements with Vinbiocare and J&J in 2022 |
| But in the meantime, we can certainly fail the void with our global CDMO partners in terms of Catalent in the United States and Aldevron and Recipharm in Poland and in Europe |
| And then perhaps one question for ARTC-810 and OTC, we recall in the past for the Phase 2 study in Europe enrollment was slightly delayed |
| So we're not doing that |
| For the three months ended December 31, 2023, we reported a net loss of approximately $8.6 million or $0.32 per diluted share, compared with a net income of $117.4 million or $4.33 per diluted share for the three months ended December 31, 2022, prior year quarter included a $200 million upfront payment from our CSL collaboration |
| So speculating what that -- how that impacts the market is going to be difficult for me to do, more appropriate for analysts on this call to do that |
| For the year ended December 31, 2023, Arcturus reported a net loss of approximately $26.6 million or $1 per diluted share, compared with net income of $9.3 million to $0.35 per diluted share in the year ended December 31, 2022 |
| This is a competitive environment |
| But it's something that we're not really concerned about at this point |
Please consider a small donation if you think this website provides you with relevant information